ANTHERA PHARMACEUTICALS,INC. (NASDAQ:ANTH) Files An 8-K Other EventsItem 8.01. Other Events.
On May 30, 2018, Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced that it will hold the Company’s 2018 annual meeting on December 3, 2018 (the “2018 Annual Meeting”). Further information regarding the 2018 Annual Meeting will be made available to stockholders in a definitive proxy statement, which will be filed with the Securities and Exchange Commission (the “SEC”).
Stockholders who meet the requirements of the proxy rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), may submit proposals to the Company’s Board of Directors (the “Board”) to be presented at the 2018 Annual Meeting. Such proposals must comply with the requirements of Rule14a-8 under the Exchange Act and be submitted in writing by notice delivered or mailed by first-classUnited States mail, postage prepaid, to our Secretary at our principal executive offices at the address set forth above no later than October 4, 2018 in order to be considered for inclusion in the proxy materials to be disseminated by the Board for the 2018 Annual Meeting.
Stockholders who desire to bring business before the 2018 Annual Meeting, other than through a shareholder proposal to the SEC’s rules, must notify the Company’s Secretary in writing and provide the information required by the provision of the Company’s Amended and Restated Bylaws dealing with shareholder proposals. Notice must be received at the Company’s principal executive offices no later than October 4, 2018. The requirements for such notice are set forth in the Company’s Amended and Restated Bylaws. The Company reserves the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these and other applicable requirements.
About ANTHERA PHARMACEUTICALS,INC. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.